|
COVID-19 and Influenza Scenario Modeling Hubs (SMH)
|
Research Initiative
|
CDC
|
FIC, NIGMS
|
Collaboration between NIH, CDC and academia for disease projections. From weather to infectious diseases, it has been shown that synergizing results from multiple models gives more reliable projections than any one model alone. The COVID-19 Scenario Modeling Hub is a collaborative effort between multiple government agencies and academic institutions to harmonize COVID-19 projections in the United States and facilitate planning and decision making at a 3-12 month time scale. Since December 2020, the COVID19 scenario modeling hub has released 12 rounds of projections on issues as varied as the impact of the vaccination program, non-pharmaceutical interventions, waning immunity, and new variants on the trajectory of cases, hospitalizations and deaths across the US. The most recent set of projections addresses the impact of Omicron. In each round of projections, a set of 4 scenarios are identified to allow alignment of model projections for collective insights. Scenarios are designed in consultation with academic modeling teams, NIH and the CDC. Between 6 and 10 models have contributed to each round. All projections are made publicly available via the COVID-19 scenario modeling hub github and website. After each round, a report summarizing key results is shared with decision-makers and public health stakeholders. There has been substantial media coverage on this effort and results have been used by CDC/ACIP to guide COVID19 vaccine recommendations. The hub expanded in 2022 to generate influenza projections. This study builds on long-standing efforts led by the Fogarty International Center's in-house research division to develop computational approaches to mitigate pandemic risk and foster collaborative network in disease modeling. This effort extends a prior collaboration titled the Multinational Influenza Seasonal Mortality Study (MISMS) to assess the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications.
|
|
COVID-19 Health and Safety Briefs
|
Training Initiative
|
CDC
|
NIEHS
|
A number of technical documents/briefs were created to provide guidance: Selection and Use of Portable Air Cleaners to Protect Workers from Exposure to SARS CoV-2; Key Information for Workplace and Training Provider; Respiratory Hazard Assessment Brief.
|
|
COVID-19 OpenData Portal
|
Research Initiative
|
ASPR
|
NCATS, NIAID, NLM
|
The NCATS OpenData COVID-19 portal is a resource designed to rapidly and openly share SARS-CoV-2 screening data and assay information with the global health community. NCATS scientists have worked to develop a number of SARS-CoV-2-related assays (18 high-throughput screens to date) to measure over 10,000 compounds, including the NCATS Pharmaceutical Collection of nearly 3,000 approved drugs, for their activity against the virus. These data include all positive and negative results from a diverse panel of repurposing screens, and can be viewed, sorted, searched and exported directly from the portal website. Screening datasets were uploaded to the website as soon as they were validated and available. This resource aims to reimagine the early translation process by sharing screening data immediately and without restrictions. We hope to enable a variety of drug repurposing activities and allow researchers to formulate and test hypotheses, prioritize research opportunities and speed the search for effective therapies against the virus and the disease it causes. In collaboration with ACTIV TRACE, the OpenData Portal has evolved to share a wider array of data, including the most comprehensive public database of in vitro therapeutic activity data available against known variants. To date, this living resource has compiled more than 17,000 activity data points from tested variants, curated from nearly 440 different publications/datasets.
|
|
COVID-19 Therapeutics Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC
|
NIAID
|
To share updates on the wide range of COVID therapeutics efforts that are progressing across the agencies
|
|
Critical Path for Rare Neurodegenerative Diseases (CP-RND)
|
Research Initiative
|
FDA
|
NINDS
|
Critical Path for Rare Neurodegenerative Diseases is a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and supporting the development and regulatory review of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases.
|
|
CTAC Ad hoc Strategic Planning Working Group (CTAC SPWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CMS
|
NCI
|
The Clinical Trials and Translational Research Advisory Committee (CTAC) SPWG was charged to re-assess NCI’s strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities.
|
|
CTAC ad hoc Working Group on Streamlining Clinical Trials (CTAC SCTWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
The Clinical Trials and Translational Research Advisory Committee (CTAC) Streamlining Clinical Trials Working Group will address the implementation of the CTAC Strategic Planning Working Groups recommendations around streamlining NCI clinical trials. The Working Group will advise NCI on ways to limit data collection in clinical trials as well as optimize the utilization of Electronic Health Records (EHRs) to support clinical trials.*The working group released its interim report in FY2023.
|
|
CURE ID
|
Research Initiative
|
FDA
|
NCATS
|
CURE ID is an internet-based repository that lets the clinical community report novel uses of existing drugs for difficult-to-treat infectious diseases through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers to facilitate the development of new treatments for neglected diseases. CURE ID is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with the World Health Organization and the Infectious Disease Society of America to assess the global utility of the CURE ID. With an $8.3 million grant from HHS ASPE;s Patient-Centered Outcomes Research Trust Fund, CURE ID is also being expanded to include case reports extracted automatically from electronic health records using the EDGE Tool. This will significantly increase the quantity of data included in CURE ID. The EDGE tool is currently being used for COVID-19 data and is now being expanded to capture data on sepsis and meningitis treatments.
|
|
CURE ID App for Infectious Disease Case Reporting
|
Research Initiative
|
FDA
|
NCI
|
CURE ID App for Infectious Disease Case Reporting
|
|
Cytokine Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NICHD, NIDCR, NIDCD
|
The Cytokine Interest Group brings together the National Institutes of Health (NIH) and Food and Drug Administration (FDA) scientists from many different areas working with cytokines as mediators of immune processes. It provides a platform for establishing networks for the exchange of ideas and reagents. Its activities comprise multiple minisymposia throughout the year and an award for the best paper in cytokine research for postdoctoral fellows working at the NIH or FDA.
|